HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $20

Benzinga Newsdesk www.benzinga.com Positive 75.4%

Neg 0% Neu 0% Pos 75.4%

HC Wainwright & Co. analyst Yi Chen maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises the price target from $19 to $20.